Operational Costs Compared: SG&A Analysis of argenx SE and Exelixis, Inc.

A Decade of SG&A Evolution: Argenx SE vs. Exelixis, Inc.

In the ever-evolving biotech landscape, operational efficiency is paramount. Over the past decade, Argenx SE and Exelixis, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Exelixis, Inc. saw a steady increase in SG&A costs, growing nearly tenfold. In 2014, their expenses were modest, but by 2023, they had surged to over 540% of their initial value. Meanwhile, Argenx SE, starting with minimal SG&A expenses, experienced an exponential rise, culminating in a staggering 16,600% increase by 2023. This dramatic growth reflects Argenx's aggressive expansion and strategic investments. As these companies continue to innovate, understanding their operational cost dynamics offers valuable insights into their strategic priorities and market positioning.